Literatures

Primary Site >> Liver Cancer

Gene >> ZHX2

1.
Journal:	Science. 1987 Sep 11;237(4820):1309-16.
Title:	Activated oncogenes in B6C3F1 mouse liver tumors: implications for risk assessment.
Author:	Reynolds, S H\|Stowers, S J\|Patterson, R M\|Maronpot, R R\|Aaronson, S A\|Anderson, M W
PMID:	3629242

2.
Journal:	Mol Cell Biol. 1988 Oct;8(10):4492-501.
Title:	Tumorigenicity of simian virus 40-hepatocyte cell lines: effect of in vitro and in vivo passage on expression of liver-specific genes and oncogenes.
Author:	Woodworth, C D\|Kreider, J W\|Mengel, L\|Miller, T\|Meng, Y L\|Isom, H C
PMID:	2460744

3.
Journal:	Sci Sin B. 1988 Nov;31(11):1325-32.
Title:	Transforming genes in duck hepatic carcinoma--mht(raf) and Ha-ras.
Author:	Tan, H\|Liu, C T\|Hong, W N\|Tang, G Y\|Zhang, S Y\|Lu, Z X\|Chen, Y Q\|Jiang, H Q\|Gu, J R
PMID:	2855457

4.
Journal:	Mol Carcinog. 1988;1(1):26-32.
Title:	Transforming activity of DNA from rat liver tumors induced by the carcinogen methyl(acetoxymethyl)nitrosamine.
Author:	Goyette, M\|Dolan, M\|Kaufmann, W\|Kaufman, D\|Shank, P R\|Fausto, N
PMID:	2855600

5.
Journal:	Hepatology. 1989 May;9(5):756-62.
Title:	Poly(A+)RNA levels of growth-, differentiation- and transformation-associated genes in the progressive development of hepatocellular carcinoma in the rat.
Author:	Huber, B E\|Heilman, C A\|Thorgeirsson, S S
PMID:	2468594

6.
Journal:	Cancer Res. 1989 Oct 1;49(19):5305-11.
Title:	Relationship between the formation of promutagenic adducts and the activation of the K-ras protooncogene in lung tumors from A/J mice treated with nitrosamines.
Author:	Belinsky, S A\|Devereux, T R\|Maronpot, R R\|Stoner, G D\|Anderson, M W
PMID:	2670201

7.
Journal:	Cancer Res. 1990 Aug 1;50(15):4818-23.
Title:	Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene.
Author:	Goodrow, T\|Reynolds, S\|Maronpot, R\|Anderson, M
PMID:	2196119

8.
Journal:	Keio J Med. 1991 Sep;40(3):139-45.
Title:	Proto-oncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5.
Author:	Saito, H\|Morizane, T\|Watanabe, T\|Kagawa, T\|Miyaguchi, S\|Kumagai, N\|Tsuchimoto, K\|Tsuchiya, M
PMID:	1661347

9.
Journal:	Cancer Res. 1991 Feb 15;51(4):1148-53.
Title:	Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice.
Author:	Candrian, U\|You, M\|Goodrow, T\|Maronpot, R R\|Reynolds, S H\|Anderson, M W
PMID:	1997158

10.
Journal:	J Med Virol. 1992 Dec;38(4):235-9.
Title:	Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines.
Author:	Farshid, M\|Tabor, E
PMID:	1335479

11.
Journal:	Int J Exp Pathol. 1992 Feb;73(1):99-114.
Title:	Pathology of spontaneous and oncogene transformed rat liver epithelial cells and derived tumours in nude mice.
Author:	Williams, A O\|Huggett, A C\|Thorgeirsson, S S
PMID:	1576082

12.
Journal:	Mol Carcinog. 1994 Mar;9(3):155-66.
Title:	Alterations in the methylation status and expression of the raf oncogene in phenobarbital-induced and spontaneous B6C3F1 mouse liver tumors.
Author:	Ray, J S\|Harbison, M L\|McClain, R M\|Goodman, J I
PMID:	7908202

13.
Journal:	Prog Clin Biol Res. 1995;391:81-101.
Title:	Hypomethylation of DNA: a possible epigenetic mechanism involved in tumor promotion.
Author:	Counts, J L\|Goodman, J I
PMID:	8532739

14.
Journal:	Mol Carcinog. 1997 Feb;18(2):97-106.
Title:	Comparison of effect of tumor promoter treatments on DNA methylation status and gene expression in B6C3F1 and C57BL/6 mouse liver and in B6C3F1 mouse liver tumors.
Author:	Counts, J L\|McClain, R M\|Goodman, J I
PMID:	9049185

15.
Journal:	Hepatology. 2001 Jul;34(1):32-41.
Title:	Roles of Akt/PKB and IKK complex in constitutive induction of NF-kappaB in hepatocellular carcinomas of transforming growth factor alpha/c-myc transgenic mice.
Author:	Factor, V\|Oliver, A L\|Panta, G R\|Thorgeirsson, S S\|Sonenshein, G E\|Arsura, M
PMID:	11431731

16.
Journal:	Mutat Res. 2001 Sep 1;480-481:219-29.
Title:	Mechanism of up-regulated gap junctional intercellular communication during chemoprevention and chemotherapy of cancer.
Author:	Trosko, J E\|Chang, C C
PMID:	11506816

17.
Journal:	J Gastroenterol. 2002;37 Suppl 13:50-4.
Title:	Hepatitis C virus and its roles in cell proliferation.
Author:	Shimotohno, Kunitada\|Watashi, Koichi\|Tsuchihara, Katsuya\|Fukuda, Katsuhiko\|Marusawa, Hiroyuki\|Hijikata, Makoto
PMID:	12109666

18.
Journal:	Cancer Res. 2002 Oct 1;62(19):5393-8.
Title:	Inhibition of hepatic endothelial E-selectin expression by C-raf antisense oligonucleotides blocks colorectal carcinoma liver metastasis.
Author:	Khatib, Abdel-Majid\|Fallavollita, Lucia\|Wancewicz, Edward V\|Monia, Brett P\|Brodt, Pnina
PMID:	12359742

19.
Journal:	Clin Exp Pharmacol Physiol. 2003 Jan-Feb;30(1-2):96-102.
Title:	RNA interference may be more potent than antisense RNA in human cancer cell lines.
Author:	Aoki, Y\|Cioca, D P\|Oidaira, H\|Kamiya, J\|Kiyosawa, K
PMID:	12542461

20.
Journal:	Gut. 2003 May;52(5):706-12.
Title:	Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma.
Author:	Tannapfel, A\|Sommerer, F\|Benicke, M\|Katalinic, A\|Uhlmann, D\|Witzigmann, H\|Hauss, J\|Wittekind, C
PMID:	12692057

21.
Journal:	Hepatol Res. 2004 Jun;29(2):113-121.
Title:	Over-expression of c-raf-1 proto-oncogene in liver cirrhosis and hepatocellular carcinoma.
Author:	Hwang, Yeo Hyeon\|Choi, Jong Young\|Kim, Soyoun\|Chung, Eun Sun\|Kim, Taeuk\|Koh, Sang Seok\|Lee, Bogman\|Bae, Si Hyun\|Kim, Jin\|Park, Young Min
PMID:	15163433

22.
Journal:	World J Gastroenterol. 2004 Dec 1;10(23):3433-40.
Title:	Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Author:	Ding, Sheng\|Gong, Bang-Dong\|Yu, Jian\|Gu, Jun\|Zhang, Hong-Yu\|Shang, Zu-Bin\|Fei, Qi\|Wang, Peng\|Zhu, Jing-De
PMID:	15526362

23.
Journal:	Oncogene. 2005 Feb 10;24(7):1290-5.
Title:	B-raf and Ha-ras mutations in chemically induced mouse liver tumors.
Author:	Jaworski, Maike\|Buchmann, Albrecht\|Bauer, Peter\|Riess, Olaf\|Schwarz, Michael
PMID:	15592514

24.
Journal:	Arch Biochem Biophys. 2005 Apr 15;436(2):285-96.
Title:	Repression of 5-aminolevulinate synthase gene by the potent tumor promoter, TPA, involves multiple signal transduction pathways.
Author:	Guberman, Alejandra S\|Scassa, Maria E\|Canepa, Eduardo T
PMID:	15797241

25.
Journal:	Biochim Biophys Acta. 2005 Sep 30;1745(3):401-10.
Title:	Rapid inhibition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling by interferon-alpha in hepatocellular carcinoma cell lines.
Author:	Inamura, Kentaro\|Matsuzaki, Yasushi\|Uematsu, Naoya\|Honda, Akira\|Tanaka, Naomi\|Uchida, Kazuhiko
PMID:	16054712

26.
Journal:	Drugs Today (Barc). 2005 Dec;41(12):773-84.
Title:	Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Author:	Strumberg, Dirk
PMID:	16474853

27.
Journal:	Am J Clin Pathol. 2006 May;125(5):740-6.
Title:	Promoter hypermethylation of a novel gene, ZHX2, in hepatocellular carcinoma.
Author:	Lv, Zili\|Zhang, Meng\|Bi, Jiong\|Xu, Fangping\|Hu, Shaowei\|Wen, Jianming
PMID:	16707376

28.
Journal:	Methods Enzymol. 2006;407:597-612.
Title:	Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Author:	Adnane, Lila\|Trail, Pamela A\|Taylor, Ian\|Wilhelm, Scott M
PMID:	16757355

29.
Journal:	Semin Oncol. 2006 Aug;33(4):392-406.
Title:	Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Author:	Gollob, Jared A\|Wilhelm, Scott\|Carter, Chris\|Kelley, Susan L
PMID:	16890795

30.
Journal:	Cancer Res. 2006 Dec 15;66(24):11851-8.
Title:	Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Author:	Liu, Li\|Cao, Yichen\|Chen, Charles\|Zhang, Xiaomei\|McNabola, Angela\|Wilkie, Dean\|Wilhelm, Scott\|Lynch, Mark\|Carter, Christopher
PMID:	17178882

31.
Journal:	Neoplasma. 2007;54(3):207-11.
Title:	Expression of zinc-fingers and homeoboxes 2 in hepatocellular carcinogenesis: a tissue microarray and clinicopathological analysis.
Author:	Hu, S\|Zhang, M\|Lv, Z\|Bi, J\|Dong, Y\|Wen, J
PMID:	17447851

32.
Journal:	Oncologist. 2007 Apr;12(4):426-37.
Title:	Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Author:	Strumberg, Dirk\|Clark, Jeffrey W\|Awada, Ahmad\|Moore, Malcolm J\|Richly, Heike\|Hendlisz, Alain\|Hirte, Hal W\|Eder, Joseph P\|Lenz, Heinz-Josef\|Schwartz, Brian
PMID:	17470685

33.
Journal:	Int J Cancer. 2007 Sep 15;121(6):1382-5.
Title:	Global gene expression in Ha-ras and B-raf mutated mouse liver tumors.
Author:	Jaworski, Maike\|Ittrich, Carina\|Hailfinger, Stephan\|Bonin, Michael\|Buchmann, Albrecht\|Schwarz, Michael\|Kohle, Christoph
PMID:	17514646

34.
Journal:	Eur J Cancer Prev. 2007 Aug;16(4):363-71.
Title:	Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma
Author:	Mukherjee, Biswajit\|Das, Tanushree\|Ghosh, Shampa\|Datta, Subrata
PMID:	17554210

35.
Journal:	Hepatology. 2007 Nov;46(5):1541-7.
Title:	The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2.
Author:	Morford, Lorri A\|Davis, Christina\|Jin, Lin\|Dobierzewska, Aneta\|Peterson, Martha L\|Spear, Brett T
PMID:	17668883

36.
Journal:	Curr Pharm Des. 2007;13(32):3279-87.
Title:	Molecular pathways and related target therapies in liver carcinoma.
Author:	Tommasi, S\|Pinto, R\|Pilato, B\|Paradiso, A
PMID:	18045179

37.
Journal:	Oncology. 2007;72 Suppl 1:30-44.
Title:	From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
Author:	Pang, Roberta W C\|Poon, Ronnie T P
PMID:	18087180

38.
Journal:	J Gastrointest Cancer. 2007;38(2-4):154-6.
Title:	Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
Author:	LaRocca, Renato V\|Hicks, Matthew D\|Mull, Lennea\|Foreman, Brenda
PMID:	19089671

39.
Journal:	Mutat Res. 2008 Feb 1;638(1-2):66-74.
Title:	Differential selection for B-raf and Ha-ras mutated liver tumors in mice with high and low susceptibility to hepatocarcinogenesis.
Author:	Buchmann, Albrecht\|Karcier, Zuleyha\|Schmid, Benjamin\|Strathmann, Julia\|Schwarz, Michael
PMID:	17928010

40.
Journal:	Cancer Chemother Pharmacol. 2008 Apr;61(4):535-48.
Title:	Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Author:	Takimoto, Chris H\|Awada, Ahmad
PMID:	18026728

41.
Journal:	World J Gastroenterol. 2008 Jan 7;14(1):1-14.
Title:	Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.
Author:	Hopfner, Michael\|Schuppan, Detlef\|Scherubl, Hans
PMID:	18176955

42.
Journal:	J Cell Mol Med. 2008 Dec;12(6B):2772-80.
Title:	ZHX2 is a repressor of alpha-fetoprotein expression in human hepatoma cell lines.
Author:	Shen, H\|Luan, F\|Liu, H\|Gao, L\|Liang, X\|Zhang, L\|Sun, W\|Ma, C
PMID:	18194454

43.
Journal:	Langenbecks Arch Surg. 2008 May;393(3):333-41.
Title:	Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model.
Author:	Lang, Sven Arke\|Brecht, Isabel\|Moser, Christian\|Obed, Aiman\|Batt, David\|Schlitt, Hans Juergen\|Geissler, Edward Kenneth\|Stoeltzing, Oliver
PMID:	18297306

44.
Journal:	Ann Hepatol. 2008 Jan-Mar;7(1):46-51.
Title:	Sorafenib, a systemic therapy for hepatocellular carcinoma.
Author:	Mendez-Sanchez, Nahum\|Vasquez-Fernandez, Francisco\|Zamora-Valdes, Daniel\|Uribe, Misael
PMID:	18376365

45.
Journal:	N Engl J Med. 2008 Jul 24;359(4):378-90.
Title:	Sorafenib in advanced hepatocellular carcinoma.
Author:	Llovet, Josep M\|Ricci, Sergio\|Mazzaferro, Vincenzo\|Hilgard, Philip\|Gane, Edward\|Blanc, Jean-Frederic\|de Oliveira, Andre Cosme\|Santoro, Armando\|Raoul, Jean-Luc\|Forner, Alejandro\|Schwartz, Myron\|Porta, Camillo\|Zeuzem, Stefan\|Bolondi, Luigi\|Greten, Tim F\|Gal
PMID:	18650514

46.
Journal:	Oncologist. 2008 Aug;13(8):845-58.
Title:	Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Author:	Dal Lago, Lissandra\|D'Hondt, Veronique\|Awada, Ahmad
PMID:	18695262

47.
Journal:	Aliment Pharmacol Ther. 2008 Dec 1;28(11-12):1269-77.
Title:	Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Author:	Chaparro, M\|Gonzalez Moreno, L\|Trapero-Marugan, M\|Medina, J\|Moreno-Otero, R
PMID:	18808443

48.
Journal:	Nan Fang Yi Ke Da Xue Xue Bao. 2008 Aug;28(9):1684-7.
Title:	[Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Author:	Chen, Feng-sheng\|Cui, Yan-zhi\|Luo, Rong-cheng\|Wu, Jing\|Zhang, Hua
PMID:	18819900

49.
Journal:	Mol Cancer Ther. 2008 Oct;7(10):3129-40.
Title:	Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Author:	Wilhelm, Scott M\|Adnane, Lila\|Newell, Philippa\|Villanueva, Augusto\|Llovet, Josep M\|Lynch, Mark
PMID:	18852116

50.
Journal:	Onkologie. 2008 Oct;31(10):550-5.
Title:	Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Author:	Zender, Lars\|Kubicka, Stefan
PMID:	18854656

51.
Journal:	Adv Ther. 2008 Nov;25(11):1089-104.
Title:	Systemic therapy of hepatocellular carcinoma: are we making progress?
Author:	Roxburgh, Patricia\|Evans, T R Jeffry
PMID:	18972075

52.
Journal:	Mol Carcinog. 2009 Jan;48(1):56-65.
Title:	Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Author:	Xie, Huahong\|Gao, Liucun\|Chai, Na\|Song, Jiugang\|Wang, Jun\|Song, Zhenshun\|Chen, Caiping\|Pan, Yanglin\|Zhao, Lina\|Sun, Shiren\|Wu, Kaichun\|Feitelson, Mark A\|Liu, Jie\|Fan, Daiming
PMID:	18506760

53.
Journal:	Liver Int. 2009 Jan;29(1):10-7.
Title:	Management of advanced hepatocellular carcinoma in the era of targeted therapy.
Author:	Yau, Thomas\|Chan, Pierre\|Epstein, Richard\|Poon, Ronnie Tung Ping
PMID:	19120940

54.
Journal:	J Cell Mol Med. 2009 Aug;13(8B):2673-83.
Title:	Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Author:	Huynh, Hung\|Ngo, Van Chanh\|Koong, Heng Nung\|Poon, Donald\|Choo, Su Pin\|Thng, Choon Hua\|Chow, Pierce\|Ong, Hock Soo\|Chung, Alexander\|Soo, Khee Chee
PMID:	19220580

55.
Journal:	Drugs. 2009;69(2):223-40.
Title:	Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Author:	Keating, Gillian M\|Santoro, Armando
PMID:	19228077

56.
Journal:	Front Biosci (Landmark Ed). 2009 Jan 1;14:3724-32.
Title:	ZHX2 and ZHX3 repress cancer markers in normal hepatocytes.
Author:	Yamada, Kazuya\|Ogata-Kawata, Hiroko\|Matsuura, Kaoru\|Kagawa, Norio\|Takagi, Katsuhiro\|Asano, Kosuke\|Haneishi, Ayumi\|Miyamoto, Kaoru
PMID:	19273305

57.
Journal:	IUBMB Life. 2009 Jun;61(6):685-92.
Title:	Tax1 enhances cancer cell proliferation via Ras-Raf-MEK-ERK signaling pathway.
Author:	Song, Chunjiao\|Wang, Weimin\|Li, Meng\|Liu, Yanxin\|Zheng, Dexian
PMID:	19472191

58.
Journal:	J Proteome Res. 2009 Aug;8(8):3987-94.
Title:	Comparative transcriptome and proteome analysis of Ha-ras and B-raf mutated mouse liver tumors.
Author:	Rignall, Benjamin\|Ittrich, Carina\|Krause, Eberhard\|Appel, Klaus E\|Buchmann, Albrecht\|Schwarz, Michael
PMID:	19476384

59.
Journal:	BMC Med. 2009 Aug 24;7:41.
Title:	Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
Author:	Zhang, Zhe\|Zhou, Xiaoyun\|Shen, Hujia\|Wang, Dexing\|Wang, Yanhong
PMID:	19698189

60.
Journal:	Clin Cancer Res. 2009 Sep 15;15(18):5820-8.
Title:	Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Author:	Ou, Da-Liang\|Shen, Ying-Chun\|Liang, Ja-Der\|Liou, Jun-Yang\|Yu, Sung-Liang\|Fan, Hsiang-Hsuan\|Wang, Da-Sheng\|Lu, Yen-Shen\|Hsu, Chiun\|Cheng, Ann-Lii
PMID:	19737956

61.
Journal:	Korean J Hepatol. 2009 Sep;15(3):299-308.
Title:	Molecular targeting for treatment of advanced hepatocellular carcinoma.
Author:	Song, Il Han
PMID:	19783879

62.
Journal:	Onco Targets Ther. 2009 Feb 18;2:261-7.
Title:	Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma.
Author:	Almhanna, Khaldoun\|Philip, Philip A
PMID:	20616913

63.
Journal:	Expert Rev Clin Pharmacol. 2009 Mar;2(2):129-36.
Title:	Sorafenib for the treatment of hepatocellular carcinoma across geographic regions.
Author:	Hsu, Chiun\|Shen, Ying-Chun\|Cheng, Ann Lii
PMID:	24410643

64.
Journal:	Cancer Chemother Pharmacol. 2010 Jan;65(2):309-18.
Title:	Effect of antisense oligomer in controlling c-raf.1 overexpression during diethylnitrosamine-induced hepatocarcinogenesis in rat.
Author:	Das, Tanushree\|Patra, Falguni\|Mukherjee, Biswajit
PMID:	19499222

65.
Journal:	J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):420-1.
Title:	Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Author:	Reig, Maria\|Bruix, Jordi
PMID:	19890601

66.
Journal:	J Hepatol. 2010 Jan;52(1):79-87.
Title:	AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Author:	Huynh, Hung\|Ngo, Van Chanh\|Koong, Heng Nung\|Poon, Donald\|Choo, Su Pin\|Toh, Han Chong\|Thng, Choon Hua\|Chow, Pierce\|Ong, Hock Soo\|Chung, Alexander\|Goh, Boon Cher\|Smith, Paul D\|Soo, Khee Chee
PMID:	19910069

67.
Journal:	Recent Results Cancer Res. 2010;184:61-70.
Title:	Sorafenib.
Author:	Hasskarl, Jens
PMID:	20072831

68.
Journal:	Expert Opin Investig Drugs. 2010 Feb;19(2):265-74.
Title:	Targeted therapy of hepatocellular cancer.
Author:	Wysocki, Piotr Jan
PMID:	20074016

69.
Journal:	Radiat Oncol. 2010 Feb 12;5:12.
Title:	Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I
Author:	Zhao, Jian-Dong\|Liu, Jin\|Ren, Zhi-Gang\|Gu, Ke\|Zhou, Zhen-Hua\|Li, Wen-Tao\|Chen, Zhen\|Xu, Zhi-Yong\|Liu, Lu-Ming\|Jiang, Guo-Liang
PMID:	20149262

70.
Journal:	Virol J. 2010 Feb 20;7:45.
Title:	Hepatitis B virus X protein upregulates HSP90alpha expression via activation of c-Myc in human hepatocarcinoma cell line, HepG2.
Author:	Li, Weihua\|Miao, Xiaohui\|Qi, Zhongtian\|Zeng, Wenting\|Liang, Jianxin\|Liang, Zengwei
PMID:	20170530

71.
Journal:	Am J Transl Res. 2010 Jan 23;2(1):105-18.
Title:	Molecular genetics of hepatocellular neoplasia.
Author:	Jain, Shilpa\|Singhal, Shashideep\|Lee, Peng\|Xu, Ruliang
PMID:	20182587

72.
Journal:	Cancer Sci. 2010 Jun;101(6):1501-10.
Title:	Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma.
Author:	Deng, Ying-Bing\|Nagae, Genta\|Midorikawa, Yutaka\|Yagi, Koichi\|Tsutsumi, Shuichi\|Yamamoto, Shogo\|Hasegawa, Kiyoshi\|Kokudo, Norihiro\|Aburatani, Hiroyuki\|Kaneda, Atsushi
PMID:	20345479

73.
Journal:	Biochem Pharmacol. 2010 Sep 1;80(5):550-60.
Title:	Molecularly targeted therapy in hepatocellular carcinoma.
Author:	Huynh, Hung
PMID:	20371362

74.
Journal:	J Gastrointest Cancer. 2010 Jun;41(2):149-52.
Title:	Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
Author:	Welker, Martin-Walter\|Zangos, Stephan\|Kriener, Susanne\|Monch, Christian\|Zeuzem, Stefan\|Trojan, Joerg
PMID:	20396977

75.
Journal:	Expert Opin Pharmacother. 2010 Aug;11(11):1943-55.
Title:	Sorafenib: a clinical and pharmacologic review.
Author:	Iyer, Renuka\|Fetterly, Gerald\|Lugade, Amit\|Thanavala, Yasmin
PMID:	20586710

76.
Journal:	Oncology. 2010 Jul;78 Suppl 1:113-24.
Title:	Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.
Author:	Kudo, Masatoshi
PMID:	20616593

77.
Journal:	Oncology. 2010 Jul;78 Suppl 1:154-66.
Title:	Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Author:	Kudo, Masatoshi\|Ueshima, Kazuomi
PMID:	20616599

78.
Journal:	Oncogene. 2010 Sep 9;29(36):4989-5005.
Title:	The role of signaling pathways in the development and treatment of hepatocellular carcinoma.
Author:	Whittaker, S\|Marais, R\|Zhu, A X
PMID:	20639898

79.
Journal:	Hepatogastroenterology. 2010 May-Jun;57(99-100):426-9.
Title:	Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China.
Author:	Qun, Wang\|Tao, Yin
PMID:	20698202

80.
Journal:	Mol Cancer. 2010 Sep 22;9:256.
Title:	Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Author:	Charette, Nicolas\|De Saeger, Christine\|Lannoy, Valerie\|Horsmans, Yves\|Leclercq, Isabelle\|Starkel, Peter
PMID:	20860815

81.
Journal:	Anticancer Res. 2010 Dec;30(12):4951-8.
Title:	PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Author:	Gedaly, Roberto\|Angulo, Paul\|Hundley, Jonathan\|Daily, Michael F\|Chen, Changguo\|Koch, Alvaro\|Evers, B Mark
PMID:	21187475

82.
Journal:	Int J Cancer. 2010 Dec 15;127(12):2949-58.
Title:	Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Author:	Wei, Gang\|Wang, Meifang\|Hyslop, Terry\|Wang, Ziqiu\|Carr, Brian I
PMID:	21351273

83.
Journal:	Hepat Med. 2010 Nov 2;2:147-55.
Title:	Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma.
Author:	Pan, Jen-Jung\|Javle, Milind\|Thinn, Mie Mie\|Hsueh, Chung-Tzu\|Hsueh, Chung-Tsen
PMID:	24367212

84.
Journal:	J Neurooncol. 2011 Jan;101(1):57-66.
Title:	Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Author:	Reardon, David A\|Vredenburgh, James J\|Desjardins, Annick\|Peters, Katherine\|Gururangan, Sridharan\|Sampson, John H\|Marcello, Jennifer\|Herndon, James E 2nd\|McLendon, Roger E\|Janney, Dorothea\|Friedman, Allan H\|Bigner, Darell D\|Friedman, Henry S
PMID:	20443129

85.
Journal:	Lab Invest. 2011 Feb;91(2):262-72.
Title:	Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma.
Author:	Yoneda, Norihide\|Sato, Yasunori\|Kitao, Azusa\|Ikeda, Hiroko\|Sawada-Kitamura, Seiko\|Miyakoshi, Masami\|Harada, Kenichi\|Sasaki, Motoko\|Matsui, Osamu\|Nakanuma, Yasuni
PMID:	20856226

86.
Journal:	Semin Cancer Biol. 2011 Feb;21(1):21-7.
Title:	Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer.
Author:	Peterson, Martha L\|Ma, Chunhong\|Spear, Brett T
PMID:	21216289

87.
Journal:	Cancer Radiother. 2011 Feb;15(1):77-80.
Title:	[Sorafenib and radiotherapy association for hepatocellular carcinoma].
Author:	Girard, N\|Mornex, F
PMID:	21239203

88.
Journal:	Hepatology. 2011 Feb;53(2):577-86.
Title:	Effect of sorafenib on murine liver regeneration.
Author:	Hora, Caroline\|Romanque, Pamela\|Dufour, Jean-Francois F
PMID:	21274878

89.
Journal:	Cancer Cell. 2011 Feb 15;19(2):232-43.
Title:	Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma.
Author:	Hou, Jin\|Lin, Li\|Zhou, Weiping\|Wang, Zhengxin\|Ding, Guoshan\|Dong, Qiongzhu\|Qin, Lunxiu\|Wu, Xiaobing\|Zheng, Yuanyuan\|Yang, Yun\|Tian, Wei\|Zhang, Qian\|Wang, Chunmei\|Zhang, Qinghua\|Zhuang, Shi-Mei\|Zheng, Limin\|Liang, Anmin\|Tao, Wenzhao\|Cao, Xuetao
PMID:	21316602

90.
Journal:	Eur J Surg Oncol. 2011 Jun;37(6):513-20.
Title:	Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma.
Author:	Chen, L\|Shi, Y\|Jiang, C-Y\|Wei, L-X\|Wang, Y-L\|Dai, G-H
PMID:	21324414

91.
Journal:	Ann Dermatol Venereol. 2011 Feb;138(2):120-3.
Title:	[Squamous cell carcinoma in a patient receiving sorafenib].
Author:	Adnot-Desanlis, L\|Bernard, P\|Reguiai, Z
PMID:	21333823

92.
Journal:	Mol Ther. 2011 Jun;19(6):1170-9.
Title:	Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Author:	Heo, Jeong\|Breitbach, Caroline J\|Moon, Anne\|Kim, Chang Won\|Patt, Rick\|Kim, Mi Kyung\|Lee, Yu Kyung\|Oh, Sung Yong\|Woo, Hyun Young\|Parato, Kelley\|Rintoul, Julia\|Falls, Theresa\|Hickman, Theresa\|Rhee, Byung-Geon\|Bell, John C\|Kirn, David H\|Hwang, Tae-Ho
PMID:	21427706

93.
Journal:	Mol Cancer Ther. 2011 Jun;10(6):1007-17.
Title:	Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Author:	Piguet, Anne-Christine\|Saar, Bettina\|Hlushchuk, Ruslan\|St-Pierre, Marie V\|McSheehy, Paul M J\|Radojevic, Vesna\|Afthinos, Maresa\|Terracciano, Luigi\|Djonov, Valentin\|Dufour, Jean-Francois
PMID:	21487053

94.
Journal:	Curr Cancer Drug Targets. 2011 Jul;11(6):714-33.
Title:	Molecular targeted therapy of hepatocellular carcinoma - results of the first clinical studies.
Author:	Wiedmann, Marcus W\|Mossner, Joachim
PMID:	21599629

95.
Journal:	PLoS One. 2011;6(5):e19967.
Title:	Growth differentiation factor 15 is induced by hepatitis C virus infection and regulates hepatocellular carcinoma-related genes.
Author:	Si, Youhui\|Liu, Xiuying\|Cheng, Min\|Wang, Maorong\|Gong, Qiaoling\|Yang, Yang\|Wang, Tianyi\|Yang, Wei
PMID:	21625435

96.
Journal:	Dis Model Mech. 2011 Nov;4(6):801-13.
Title:	A high level of liver-specific expression of oncogenic Kras(V12) drives robust liver tumorigenesis in transgenic zebrafish.
Author:	Nguyen, Anh Tuan\|Emelyanov, Alexander\|Koh, Chor Hui Vivien\|Spitsbergen, Jan M\|Lam, Siew Hong\|Mathavan, Sinnakaruppan\|Parinov, Serguei\|Gong, Zhiyuan
PMID:	21729876

97.
Journal:	Cancer Biol Ther. 2011 Sep 15;12(6):531-8.
Title:	c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Author:	Carr, Brian I\|Wang, Ziqiu\|Wang, Meifang\|Cavallini, Aldo\|D'Alessandro, Rosalba\|Refolo, Maria Gratzia
PMID:	21734462

98.
Journal:	J Pathol. 2011 Sep;225(1):19-28.
Title:	A DeltaRaf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures.
Author:	He, Shuning\|Krens, Sf Gabby\|Zhan, Huiqing\|Gong, Zhiyuan\|Hogendoorn, Pancras Cw\|Spaink, Herman P\|Snaar-Jagalska, B Ewa
PMID:	21744342

99.
Journal:	FEBS J. 2011 Sep;278(18):3494-507.
Title:	Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Author:	Manov, Irena\|Pollak, Yulia\|Broneshter, Rinata\|Iancu, Theodore C
PMID:	21790999

100.
Journal:	Dig Dis. 2011;29(3):273-7.
Title:	Molecular targeted therapy for hepatocellular carcinoma: bench to bedside.
Author:	Kudo, Masatoshi
PMID:	21829017

101.
Journal:	J Korean Med Sci. 2011 Dec;26(12):1563-8.
Title:	Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
Author:	Kim, Heesue\|Lim, Ho Yeong
PMID:	22147992

102.
Journal:	Med Mol Morphol. 2011 Dec;44(4):183-9.
Title:	Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Author:	Matsuda, Yasunobu\|Fukumoto, Manabu
PMID:	22179180

103.
Journal:	Int J Cancer. 2012 Aug 1;131(3):548-57.
Title:	Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Author:	Shimizu, Satoshi\|Takehara, Tetsuo\|Hikita, Hayato\|Kodama, Takahiro\|Tsunematsu, Hinako\|Miyagi, Takuya\|Hosui, Atsushi\|Ishida, Hisashi\|Tatsumi, Tomohide\|Kanto, Tatsuya\|Hiramatsu, Naoki\|Fujita, Naonobu\|Yoshimori, Tamotsu\|Hayashi, Norio
PMID:	21858812

104.
Journal:	Dis Model Mech. 2012 Jan;5(1):63-72.
Title:	An inducible kras(V12) transgenic zebrafish model for liver tumorigenesis and chemical drug screening.
Author:	Nguyen, Anh Tuan\|Emelyanov, Alexander\|Koh, Chor Hui Vivien\|Spitsbergen, Jan M\|Parinov, Serguei\|Gong, Zhiyuan
PMID:	21903676

105.
Journal:	Cancer Sci. 2012 Jan;103(1):26-33.
Title:	Transforming growth factor-beta-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.
Author:	Nakamura, Masaki\|Kitaura, Jiro\|Enomoto, Yutaka\|Lu, Yang\|Nishimura, Koutarou\|Isobe, Masamichi\|Ozaki, Katsutoshi\|Komeno, Yukiko\|Nakahara, Fumio\|Oki, Toshihiko\|Kume, Haruki\|Homma, Yukio\|Kitamura, Toshio
PMID:	21943131

106.
Journal:	J Virol. 2012 Feb;86(3):1544-54.
Title:	Activation of the Ras/Raf/MEK pathway facilitates hepatitis C virus replication via attenuation of the interferon-JAK-STAT pathway.
Author:	Zhang, Qi\|Gong, Rui\|Qu, Jing\|Zhou, Yijing\|Liu, Weiyong\|Chen, Mingzhou\|Liu, Yingle\|Zhu, Ying\|Wu, Jianguo
PMID:	22114332

107.
Journal:	Curr Med Chem. 2012;19(7):938-44.
Title:	Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Author:	Ranieri, G\|Gadaleta-Caldarola, G\|Goffredo, V\|Patruno, R\|Mangia, A\|Rizzo, A\|Sciorsci, R L\|Gadaleta, C D
PMID:	22214462

108.
Journal:	J Surg Res. 2012 Aug;176(2):542-8.
Title:	PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Author:	Gedaly, Roberto\|Angulo, Paul\|Hundley, Jonathan\|Daily, Michael F\|Chen, Changguo\|Evers, B Mark
PMID:	22261591

109.
Journal:	Oncol Rep. 2012 May;27(5):1303-11.
Title:	Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
Author:	Ibrahim, Nuha\|Yu, Yan\|Walsh, William R\|Yang, Jia-Lin
PMID:	22323095

110.
Journal:	Anticancer Drugs. 2012 Jun;23(5):525-33.
Title:	Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Author:	Heravi, Mitra\|Tomic, Nada\|Liang, LiHeng\|Devic, Slobodan\|Holmes, Joseph\|Deblois, Francois\|Radzioch, Danuta\|Muanza, Thierry
PMID:	22357220

111.
Journal:	Gastroenterology. 2012 Jun;142(7):1559-70.e2.
Title:	Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E.
Author:	Yue, Xuetian\|Zhang, Zhenyu\|Liang, Xiaohong\|Gao, Lifen\|Zhang, Xiaoning\|Zhao, Di\|Liu, Xiao\|Ma, Hongxin\|Guo, Min\|Spear, Brett T\|Gong, Yaoqin\|Ma, Chunhong
PMID:	22406477

112.
Journal:	J Hepatol. 2012 Jul;57(1):77-83.
Title:	Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway.
Author:	Takeishi, Kazuki\|Taketomi, Akinobu\|Shirabe, Ken\|Toshima, Takeo\|Motomura, Takashi\|Ikegami, Toru\|Yoshizumi, Tomoharu\|Sakane, Fumio\|Maehara, Yoshihiko
PMID:	22425622

113.
Journal:	Dig Dis Sci. 2012 May;57(5):1122-9.
Title:	Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Author:	Xie, Bingru\|Wang, David H\|Spechler, Stuart Jon
PMID:	22451120

114.
Journal:	Expert Opin Pharmacother. 2012 May;13(7):1059-67.
Title:	Sorafenib in liver cancer.
Author:	Woo, Hyun Young\|Heo, Jeong
PMID:	22519770

115.
Journal:	Anticancer Agents Med Chem. 2012 Nov;12(9):1088-97.
Title:	Rational drug design for identifying novel multi-target inhibitors for hepatocellular carcinoma.
Author:	Temirak, Ahmed\|Abdulla, Mona\|Elhefnawi, Mahmoud
PMID:	22583422

116.
Journal:	Br J Cancer. 2012 Jun 5;106(12):1997-2003.
Title:	Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
Author:	Hagiwara, S\|Kudo, M\|Nagai, T\|Inoue, T\|Ueshima, K\|Nishida, N\|Watanabe, T\|Sakurai, T
PMID:	22596232

117.
Journal:	Anticancer Res. 2012 Jul;32(7):2531-6.
Title:	The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Author:	Gedaly, Roberto\|Angulo, Paul\|Chen, Changguo\|Creasy, Kate Townsend\|Spear, Brett T\|Hundley, Jonathan\|Daily, Michael F\|Shah, Malay\|Evers, B Mark
PMID:	22753710

118.
Journal:	OMICS. 2012 Nov;16(11):579-88.
Title:	Analysis of possible mechanisms accounting for raf-1 kinase inhibitor protein downregulation in hepatocellular carcinoma.
Author:	Poma, Paola\|Labbozzetta, Manuela\|Vivona, Nicoletta\|Porcasi, Rossana\|D'Alessandro, Natale\|Notarbartolo, Monica
PMID:	23095110

119.
Journal:	Expert Rev Anticancer Ther. 2012 Oct;12(10):1347-57.
Title:	Pathways and targets in hepatocellular carcinoma.
Author:	Psyrri, Amanda\|Arkadopoulos, Nikolaos\|Vassilakopoulou, Maria\|Smyrniotis, Vassilios\|Dimitriadis, George
PMID:	23176622

120.
Journal:	Oncol Res. 2012;20(2-3):113-21.
Title:	PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
Author:	Ruan, Zhi-Ping\|Xu, Rui\|Lv, Yi\|Tian, Tao\|Wang, Wen-Juan\|Guo, Hui\|Nan, Ke-Jun
PMID:	23193917

121.
Journal:	BMC Cancer. 2012 Dec 11;12:590.
Title:	Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Author:	Fairfax, B P\|Pratap, S\|Roberts, I S D\|Collier, J\|Kaplan, R\|Meade, A M\|Ritchie, A W\|Eisen, T\|Macaulay, V M\|Protheroe, A
PMID:	23231599

122.
Journal:	Case Rep Gastroenterol. 2012 Sep;6(3):784-9.
Title:	IGF-II Producing Hepatocellular Carcinoma Treated with Sorafenib: Metabolic Complications and a Foresight to Molecular Targeting Therapy to the IGF Signal.
Author:	Okushin, Kazuya\|Asaoka, Yoshinari\|Fukuda, Izumi\|Fujiwara, Naoto\|Minami, Tatsuya\|Sato, Masaya\|Mikami, Shintaro\|Uchino, Koji\|Enooku, Kenichiro\|Kondo, Yuji\|Tateishi, Ryosuke\|Goto, Tadashi\|Shiina, Shuichiro\|Yoshida, Haruhiko\|Koike, Kazuhiko
PMID:	23341802

123.
Journal:	J Cell Physiol. 2013 Feb;228(2):292-7.
Title:	Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery.
Author:	Carr, Brian I\|Cavallini, Aldo\|Lippolis, Catia\|D'Alessandro, Rosalba\|Messa, Caterina\|Refolo, Maria G\|Tafaro, Angela
PMID:	22777740

124.
Journal:	J Surg Oncol. 2013 Mar;107(4):393-401.
Title:	RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Author:	Shi, Ji-Hua\|Liu, Shu-Zheng\|Wierod, Lene\|Scholz, Hanne\|Anmarkrud, Jarl Andreas\|Huitfeldt, Henrik S\|Zhang, Shui-Jun\|Line, Pal-Dag
PMID:	22927239

125.
Journal:	Curr Cancer Drug Targets. 2013 Mar;13(3):300-12.
Title:	Targeting tyrosine kinase receptors in hepatocellular carcinoma.
Author:	Muntane, Jordi\|De la Rosa, Angel J\|Docobo, Fernando\|Garcia-Carbonero, Rocio\|Padillo, Francisco J
PMID:	23016985

126.
Journal:	Hepatol Res. 2013 Feb;43(2):147-54.
Title:	Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update.
Author:	Gauthier, Angela\|Ho, Mitchell
PMID:	23145926

127.
Journal:	Oncogene. 2013 Oct 10;32(41):4871-2.
Title:	Claudin-1 as a promoter of EMT in hepatocellular carcinoma.
Author:	Stebbing, J\|Filipovic, A\|Giamas, G
PMID:	23318416

128.
Journal:	Hepatol Res. 2013 Aug;43(8):820-5.
Title:	Recent topics on alpha-fetoprotein.
Author:	Nakao, Kazuhiko\|Ichikawa, Tatsuki
PMID:	23347387

129.
Journal:	Mol Pharmacol. 2013 May;83(5):1109-19.
Title:	Neuroglobin, a novel intracellular hexa-coordinated globin, functions as a tumor suppressor in hepatocellular carcinoma via Raf/MAPK/Erk.
Author:	Zhang, Jun\|Lan, Shu Jue\|Liu, Qian Rong\|Liu, Ju Mei\|Chen, Xiao Qian
PMID:	23478801

130.
Journal:	Proteomics Clin Appl. 2013 Jun;7(5-6):403-15.
Title:	Comparative mitochondrial proteomic analysis of hepatocellular carcinoma from patients.
Author:	Ye, Yunbin\|Huang, Aimin\|Huang, Chuanzhong\|Liu, Jingfeng\|Wang, Bin\|Lin, Kecan\|Chen, Qiang\|Zeng, Yongyi\|Chen, Huijing\|Tao, Xuan\|Wei, Guangya\|Wu, Yanbin
PMID:	23589362

131.
Journal:	Invest New Drugs. 2013 Aug;31(4):1078-86.
Title:	Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis.
Author:	Belum, Viswanath Reddy\|Wu, Shenhong\|Lacouture, Mario E
PMID:	23700287

132.
Journal:	BMC Cancer. 2013 May 30;13:267.
Title:	Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Author:	Chang, Alex Y\|Wang, Miao
PMID:	23721490

133.
Journal:	Bioorg Med Chem Lett. 2013 Jul 1;23(13):3732-7.
Title:	Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
Author:	Hwang, Sung Hee\|Wecksler, Aaron T\|Zhang, Guodong\|Morisseau, Christophe\|Nguyen, Long V\|Fu, Samuel H\|Hammock, Bruce D
PMID:	23726028

134.
Journal:	Cell Death Dis. 2013 Jun 6;4:e657.
Title:	Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells.
Author:	Zhang, Z\|Miao, L\|Lv, C\|Sun, H\|Wei, S\|Wang, B\|Huang, C\|Jiao, B
PMID:	23744357

135.
Journal:	J Surg Res. 2013 Nov;185(1):225-30.
Title:	PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Author:	Gedaly, Roberto\|Galuppo, Roberto\|Musgrave, Yolanda\|Angulo, Paul\|Hundley, Jonathan\|Shah, Malay\|Daily, Michael F\|Chen, Changguo\|Cohen, Donald A\|Spear, Brett T\|Evers, B Mark
PMID:	23769634

136.
Journal:	BMC Cancer. 2013 Jul 29;13:363.
Title:	Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Author:	Deng, Lifen\|Ren, Zhenggang\|Jia, Qingan\|Wu, Weizhong\|Shen, Hujia\|Wang, Yanhong
PMID:	23895220

137.
Journal:	Mol Med Rep. 2013 Nov;8(5):1531-6.
Title:	Construction of a recombinant eukaryotic human ZHX1 gene expression plasmid and the role of ZHX1 in hepatocellular carcinoma.
Author:	Wang, Jianping\|Liu, Dejie\|Liang, Xiaohong\|Gao, Lifen\|Yue, Xuetian\|Yang, Yang\|Ma, Chunhong\|Liu, Jun
PMID:	24064680

138.
Journal:	Zhonghua Gan Zang Bing Za Zhi. 2013 Nov;21(11):845-9.
Title:	[Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Author:	Deng, Li-fen\|Wang, Yan-hong\|Jia, Qing-an\|Ren, Zheng-gang\|Shen, Hu-jia\|Sun, Xiao-jing\|Li, Jing-huan
PMID:	24331695

139.
Journal:	PLoS One. 2013 Dec 31;8(12):e83627.
Title:	BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Author:	Huang, Wei-Chien\|Hsieh, Yi-Ling\|Hung, Chao-Ming\|Chien, Pei-Hsuan\|Chien, Yu-Fong\|Chen, Lei-Chin\|Tu, Chih-Yen\|Chen, Chia-Hung\|Hsu, Sheng-Chieh\|Lin, Yueh-Ming\|Chen, Yun-Ju
PMID:	24391798

140.
Journal:	Asian Pac J Cancer Prev. 2013;14(12):7367-9.
Title:	Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Author:	Berk, Veli\|Kaplan, Mehmet Ali\|Tonyali, Onder\|Buyukberber, Suleyman\|Balakan, Ozan\|Ozkan, Metin\|Demirci, Umut\|Ozturk, Turkan\|Bilici, Ahmet\|Tastekin, Didem\|Ozdemir, Nuriye\|Unal, Olcun Umit\|Oflazoglu, Utku\|Turkmen, Esma\|Erdogan, Bulent\|Uyeturk, Ummugul\|Oksuzo
PMID:	24460304

141.
Journal:	J Carcinog. 2013 Dec 31;12:22.
Title:	Targeted therapies in development for non-small cell lung cancer.
Author:	Reungwetwattana, Thanyanan\|Dy, Grace Kho
PMID:	24574860

142.
Journal:	Biomed Rep. 2013 Jul;1(4):604-608.
Title:	The fibroblast growth factor receptor 2-mediated extracellular signal-regulated kinase 1/2 signaling pathway plays is important in regulating excision repair cross-complementary gene 1 expression in hepatocellular carcinoma.
Author:	Chen, Gang\|Qiu, Hong\|Ke, Shandong\|Hu, Shaoming\|Yu, Shiying\|Zou, Shengquan
PMID:	24648994

143.
Journal:	Mol Clin Oncol. 2013 Jan;1(1):29-34.
Title:	Exogenous albumin inhibits sorafenib-induced cytotoxicity in human cancer cell lines.
Author:	Kanno, Syu-Ichi\|Itoh, Katsuyuki\|Suzuki, Naoto\|Tomizawa, Ayako\|Yomogida, Shin\|Ishikawa, Masaaki
PMID:	24649118

144.
Journal:	Curr Med Chem. 2014;21(8):966-74.
Title:	Targeted therapies in hepatocellular carcinoma.
Author:	Bronte, F\|Bronte, G\|Cusenza, S\|Fiorentino, E\|Rolfo, C\|Cicero, G\|Bronte, E\|Di Marco, V\|Firenze, A\|Angarano, G\|Fontana, T\|Russo, A
PMID:	23992323

145.
Journal:	Mol Cancer Ther. 2014 Jan;13(1):221-9.
Title:	Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
Author:	Vin, Harina\|Ching, Grace\|Ojeda, Sandra S\|Adelmann, Charles H\|Chitsazzadeh, Vida\|Dwyer, David W\|Ma, Haiching\|Ehrenreiter, Karin\|Baccarini, Manuela\|Ruggieri, Rosamaria\|Curry, Jonathan L\|Ciurea, Ana M\|Duvic, Madeleine\|Busaidy, Naifa L\|Tannir, Nizar M\|Tsai, K
PMID:	24170769

146.
Journal:	Cancer Biol Ther. 2014 Jan;15(1):1-2.
Title:	Multi-kinase inhibition in ovarian cancer.
Author:	Dent, Paul
PMID:	24309512

147.
Journal:	Oncol Rep. 2014 Mar;31(3):1147-56.
Title:	Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Author:	Walter, Ingrid\|Wolfesberger, Birgitt\|Miller, Ingrid\|Mair, Georg\|Burger, Stefanie\|Galle, Birgit\|Steinborn, Ralf
PMID:	24378831

148.
Journal:	Tumour Biol. 2014 May;35(5):4377-80.
Title:	Clinical significance of RKIP mRNA expression in non-small cell lung cancer.
Author:	Wang, Qin\|Wu, Xiaodong\|Wu, Ting\|Li, Gui-mei\|Shi, Yi
PMID:	24420151

149.
Journal:	Transplant Proc. 2014 Jan-Feb;46(1):241-4.
Title:	Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Author:	De Simone, P\|Crocetti, L\|Pezzati, D\|Bargellini, I\|Ghinolfi, D\|Carrai, P\|Leonardi, G\|Della Pina, C\|Cioni, D\|Pollina, L\|Campani, D\|Bartolozzi, C\|Lencioni, R\|Filipponi, F
PMID:	24507059

150.
Journal:	RNA. 2014 Apr;20(4):505-15.
Title:	Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development.
Author:	Shilo, Asaf\|Ben Hur, Vered\|Denichenko, Polina\|Stein, Ilan\|Pikarsky, Eli\|Rauch, Jens\|Kolch, Walter\|Zender, Lars\|Karni, Rotem
PMID:	24572810

151.
Journal:	Dig Dis Sci. 2014 Aug;59(8):1688-97.
Title:	Molecular therapies in hepatocellular carcinoma: what can we target?
Author:	Galuppo, Roberto\|Ramaiah, Dinesh\|Ponte, Oscar Moreno\|Gedaly, Roberto
PMID:	24573715

152.
Journal:	Anticancer Res. 2014 Apr;34(4):1519-30.
Title:	Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Author:	Smolle, Elisabeth\|Taucher, Valentin\|Petru, Edgar\|Haybaeck, Johannes
PMID:	24692678

153.
Journal:	Anticancer Res. 2014 Apr;34(4):1709-13.
Title:	Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways.
Author:	Galuppo, Roberto\|Maynard, Erin\|Shah, Malay\|Daily, Michael F\|Chen, Changguo\|Spear, Brett T\|Gedaly, Roberto
PMID:	24692700

154.
Journal:	Recent Results Cancer Res. 2014;201:145-64.
Title:	Sorafenib: targeting multiple tyrosine kinases in cancer.
Author:	Hasskarl, Jens
PMID:	24756790

155.
Journal:	Recent Results Cancer Res. 2014;201:185-96.
Title:	Regorafenib.
Author:	Ettrich, Thomas J\|Seufferlein, Thomas
PMID:	24756792

156.
Journal:	Cancer Res. 2014 Aug 15;74(16):4515-25.
Title:	beta-catenin activation in a novel liver progenitor cell type is sufficient to cause hepatocellular carcinoma and hepatoblastoma.
Author:	Mokkapati, Sharada\|Niopek, Katharina\|Huang, Le\|Cunniff, Kegan J\|Ruteshouser, E Cristy\|deCaestecker, Mark\|Finegold, Milton J\|Huff, Vicki
PMID:	24848510

157.
Journal:	Biomaterials. 2014 Aug;35(26):7479-87.
Title:	Therapeutic effect of a multi-targeted imidazolium compound in hepatocellular carcinoma.
Author:	Gopalan, Began\|Narayanan, Karthikeyan\|Ke, Zhiyuan\|Lu, Ting\|Zhang, Yugen\|Zhuo, Lang
PMID:	24912819

158.
Journal:	Sci Rep. 2014 Jul 1;4:5518.
Title:	Eupolyphaga sinensis walker displays inhibition on hepatocellular carcinoma through regulating cell growth and metastasis signaling.
Author:	Zhang, Yanmin\|Zhan, Yingzhuan\|Zhang, Dongdong\|Dai, Bingling\|Ma, Weina\|Qi, Junpeng\|Liu, Rui\|He, Langchong
PMID:	24980220

159.
Journal:	Oncotarget. 2014 Jul 30;5(14):5819-31.
Title:	Novel celastrol derivatives inhibit the growth of hepatocellular carcinoma patient-derived xenografts.
Author:	Wei, Wei\|Wu, Song\|Wang, Xiaolin\|Sun, Chris Kin-Wai\|Yang, Xiaoyang\|Yan, Xinrui\|Chua, Mei-Sze\|So, Samuel
PMID:	25051375

160.
Journal:	Oncol Lett. 2014 Sep;8(3):1249-1254.
Title:	Mutation analysis of key genes in RAS/RAF and PI3K/PTEN pathways in Chinese patients with hepatocellular carcinoma.
Author:	Hou, Wenmin\|Liu, Jibin\|Chen, Peizhan\|Wang, Hui\|Ye, Bang-Ce\|Qiang, Fulin
PMID:	25120700

161.
Journal:	Int J Biochem Cell Biol. 2014 Oct;55:129-35.
Title:	Reduced nucleic ZHX2 involves in oncogenic activation of glypican 3 in human hepatocellular carcinoma.
Author:	Luan, Fang\|Liu, Peng\|Ma, Hongxin\|Yue, Xuetian\|Liu, Jun\|Gao, Lifen\|Liang, Xiaohong\|Ma, Chunhong
PMID:	25195714

162.
Journal:	Yao Xue Xue Bao. 2014 Jun;49(6):861-8.
Title:	[Anti-tumor activity and mechanism of T03 in vitro and in vivo].
Author:	Tang, Ke\|Yang, Han-Ze\|Li, Yan\|Tian, Kang\|Li, Chao\|Zhou, Wan-Qi\|Niu, Fei\|Feng, Zhi-Qiang\|Chen, Xiao-Guang
PMID:	25212033

163.
Journal:	PLoS One. 2014 Sep 17;9(9):e107149.
Title:	Fatty acid esters of phloridzin induce apoptosis of human liver cancer cells through altered gene expression.
Author:	Nair, Sandhya V G\|Ziaullah\|Rupasinghe, H P Vasantha
PMID:	25229655

164.
Journal:	Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):831-42.
Title:	Integration of genomic information in the clinical management of HCC.
Author:	Quetglas, Iris M\|Moeini, Agrin\|Pinyol, Roser\|Llovet, Josep M
PMID:	25260311

165.
Journal:	Oncol Rep. 2014 Dec;32(6):2687-95.
Title:	Identification of PAQR3 as a new candidate tumor suppressor in hepatocellular carcinoma.
Author:	Wu, Hong Ge\|Zhang, Wen Jie\|Ding, Qian\|Peng, Gang\|Zou, Zhen Wei\|Liu, Ting\|Cao, Ru Bo\|Fei, Shi Jiang\|Li, Peng Cheng\|Yang, Kun Yu\|Hu, Jian Li\|Dai, Xiang Fang\|Wu, Gang\|Li, Pin Dong
PMID:	25310770

166.
Journal:	Semin Liver Dis. 2014 Nov;34(4):363-75.
Title:	Molecular profiling of liver tumors: classification and clinical translation for decision making.
Author:	Pinyol, Roser\|Nault, Jean Charles\|Quetglas, Iris M\|Zucman-Rossi, Jessica\|Llovet, Josep M
PMID:	25369299

167.
Journal:	Dig Dis. 2014;32(6):733-9.
Title:	Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Author:	Arizumi, Tadaaki\|Ueshima, Kazuomi\|Chishina, Hirokazu\|Kono, Masashi\|Takita, Masahiro\|Kitai, Satoshi\|Inoue, Tatsuo\|Yada, Norihisa\|Hagiwara, Satoru\|Minami, Yasunori\|Sakurai, Toshiharu\|Nishida, Naoshi\|Kudo, Masatoshi
PMID:	25376291

168.
Journal:	Zhong Yao Cai. 2014 Nov;37(11):1938-46.
Title:	[Study on synergistic effect of sodium cantharidinate combined with chemotherapeutic drugs on hepatic carcinoma and its effective mechanism].
Author:	Zhao, Ruo-lin\|Chen, Mei-juan\|Zhao, Feng-ming\|Xu, Dong-qing\|Zhang, Xu\|Zhou, Kun-fu
PMID:	26027111

169.
Journal:	Hepatogastroenterology. 2014 Jun;61(132):954-7.
Title:	Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Author:	Li, Jinpeng\|Wang, Lijun\|Cong, Ning\|Shi, Congcong\|Bu, Wenzhe\|Song, Jinlong\|Chen, Hua
PMID:	26158148

170.
Journal:	Thorac Cancer. 2014 Nov;5(6):487-93.
Title:	Overview of fundamental study of pazopanib in cancer.
Author:	Zhao, Hong-Lin\|Yang, Fan\|Huang, Xin\|Zhou, Qing-Hua
PMID:	26767042

171.
Journal:	J Hepatocell Carcinoma. 2014 Jun 12;1:85-99.
Title:	Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives.
Author:	Hsu, Chih-Hung\|Shen, Ying-Chun\|Shao, Yu-Yun\|Hsu, Chiun\|Cheng, Ann-Lii
PMID:	27508178

172.
Journal:	Oncotarget. 2015 Jan 20;6(2):1049-63.
Title:	ZHX2 enhances the cytotoxicity of chemotherapeutic drugs in liver tumor cells by repressing MDR1 via interfering with NF-YA.
Author:	Ma, Hongxin\|Yue, Xuetian\|Gao, Lifen\|Liang, Xiaohong\|Yan, Wenjiang\|Zhang, Zhenyu\|Shan, Haixia\|Zhang, Hualin\|Spear, Brett T\|Ma, Chunhong
PMID:	25473899

173.
Journal:	Biochim Biophys Acta. 2015 Mar;1853(3):539-48.
Title:	MAPK signaling triggers transcriptional induction of cFOS during amino acid limitation of HepG2 cells.
Author:	Shan, Jixiu\|Donelan, William\|Hayner, Jaclyn N\|Zhang, Fan\|Dudenhausen, Elizabeth E\|Kilberg, Michael S
PMID:	25523140

174.
Journal:	Arch Pathol Lab Med. 2015 Jan;139(1):14-23.
Title:	Application of immunohistochemistry in gastrointestinal and liver neoplasms: new markers and evolving practice.
Author:	Chen, Zongming Eric\|Lin, Fan
PMID:	25549141

175.
Journal:	Carcinogenesis. 2015 Mar;36(3):378-89.
Title:	Rac1 promotes diethylnitrosamine (DEN)-induced formation of liver tumors.
Author:	Bopp, Anita\|Wartlick, Friedrich\|Henninger, Christian\|Schwarz, Michael\|Kaina, Bernd\|Fritz, Gerhard
PMID:	25556150

176.
Journal:	Mol Cancer. 2015 Feb 3;14:18.
Title:	Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Author:	Ju, Bensheng\|Chen, Wenbiao\|Orr, Brent A\|Spitsbergen, Jan M\|Jia, Sujuan\|Eden, Christopher J\|Henson, Hannah E\|Taylor, Michael R
PMID:	25644510

177.
Journal:	Eur J Pharmacol. 2015 May 5;754:105-14.
Title:	Hydroxysafflor yellow A inhibits angiogenesis of hepatocellular carcinoma via blocking ERK/MAPK and NF-kappaB signaling pathway in H22 tumor-bearing mice.
Author:	Yang, Fangfang\|Li, Jingmin\|Zhu, Jinhui\|Wang, Dong\|Chen, Shaoshui\|Bai, Xianyong
PMID:	25720342

178.
Journal:	Am J Pathol. 2015 Apr;185(4):1135-44.
Title:	Methionine adenosyltransferase 2B-GIT1 complex serves as a scaffold to regulate Ras/Raf/MEK1/2 activity in human liver and colon cancer cells.
Author:	Peng, Hui\|Li, Tony W H\|Yang, Heping\|Moyer, Mary P\|Mato, Jose M\|Lu, Shelly C
PMID:	25794709

179.
Journal:	Antiviral Res. 2015 Jun;118:93-102.
Title:	The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
Author:	Descamps, Veronique\|Helle, Francois\|Louandre, Christophe\|Martin, Elodie\|Brochot, Etienne\|Izquierdo, Laure\|Fournier, Carole\|Hoffmann, Thomas W\|Castelain, Sandrine\|Duverlie, Gilles\|Galmiche, Antoine\|Francois, Catherine
PMID:	25823619

180.
Journal:	Eur J Clin Invest. 2015 Jun;45(6):609-23.
Title:	The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Author:	Delire, Benedicte\|Starkel, Peter
PMID:	25832714

181.
Journal:	Anticancer Res. 2015 Apr;35(4):1967-76.
Title:	Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Author:	Ha, Tae-Yong\|Hwang, Shin\|Moon, Ki-Myeong\|Won, You-Jin\|Song, Gi-Won\|Kim, Nayoung\|Tak, Eunyoung\|Ryoo, Baek-Yeol\|Hong, Hea-Nam
PMID:	25862849

182.
Journal:	J Hepatol. 2015 Sep;63(3):651-60.
Title:	PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Author:	Han, Tao\|Xiang, Dai-Min\|Sun, Wen\|Liu, Na\|Sun, Huan-Lin\|Wen, Wen\|Shen, Wei-Feng\|Wang, Ruo-Yu\|Chen, Cheng\|Wang, Xue\|Cheng, Zhuo\|Li, Heng-Yu\|Wu, Meng-Chao\|Cong, Wen-Ming\|Feng, Gen-Sheng\|Ding, Jin\|Wang, Hong-Yang
PMID:	25865556

183.
Journal:	Oncotarget. 2015 May 10;6(13):11627-39.
Title:	psi-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Author:	Ding, Jin\|Wen, Wen\|Xiang, Daimin\|Yin, Peipei\|Liu, Yanfang\|Liu, Chang\|He, Guoping\|Cheng, Zhuo\|Yin, Jianpeng\|Sheng, Chunquan\|Zhang, Wen\|Nan, Fajun\|Ye, Wencai\|Zhang, Xiuli\|Wang, Hongyang
PMID:	25890498

184.
Journal:	Oncotarget. 2015 May 20;6(14):12340-56.
Title:	Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Author:	Jiang, Xiufeng\|Feng, Kang\|Zhang, Ye\|Li, Zengyao\|Zhou, Fan\|Dou, Huiqiang\|Wang, Tong
PMID:	25895026

185.
Journal:	Clin Cancer Res. 2015 Oct 1;21(19):4420-30.
Title:	Hepatitis B Virus X Protein (HBx) Is Responsible for Resistance to Targeted Therapies in Hepatocellular Carcinoma: Ex Vivo Culture Evidence.
Author:	Huang, Pinbo\|Zhuang, Baoxiong\|Zhang, Heyun\|Yan, Haiyan\|Xiao, Zhiyu\|Li, Wenbin\|Zhang, Jianlong\|Tang, Qibin\|Hu, Kaishun\|Koeffler, H Phillip\|Wang, Jie\|Yin, Dong
PMID:	26059188

186.
Journal:	Cell Physiol Biochem. 2015;36(3):1223-36.
Title:	Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway.
Author:	Tang, Wenqing\|Feng, Xuemei\|Zhang, Si\|Ren, Zhenggang\|Liu, Yinkun\|Yang, Biwei\|lv, Bei\|Cai, Yu\|Xia, Jinglin\|Ge, Ningling
PMID:	26138883

187.
Journal:	Oncotarget. 2015 Sep 29;6(29):27953-65.
Title:	Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Author:	Ou, Da-Liang\|Shyue, Song-Kun\|Lin, Liang-In\|Feng, Zi-Rui\|Liou, Jun-Yang\|Fan, Hsiang-Hsuan\|Lee, Bin-Shyun\|Hsu, Chiun\|Cheng, Ann-Lii
PMID:	26172295

188.
Journal:	Sci Rep. 2015 Jul 20;5:12366.
Title:	TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection.
Author:	Wang, Cheng-Hao\|Guo, Zhong-Yi\|Chen, Ze-Ting\|Zhi, Xu-Ting\|Li, Deng-Ke\|Dong, Zhao-Ru\|Chen, Zhi-Qiang\|Hu, San-Yuan\|Li, Tao
PMID:	26190376

189.
Journal:	Anticancer Drugs. 2015 Oct;26(9):1004-7.
Title:	A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Author:	Sereno, Maria\|Moreno, Victor\|Moreno Rubio, Juan\|Gomez-Raposo, Cesar\|Garcia Sanchez, Sagrario\|Hernandez Jusdado, Rebeca\|Falagan, Sandra\|Zambrana Tebar, Francisco\|Casado Saenz, Enrique
PMID:	26237499

190.
Journal:	Hepatology. 2015 Dec;62(6):1791-803.
Title:	Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
Author:	Guan, Dong-Xian\|Shi, Jie\|Zhang, Yang\|Zhao, Jiang-Sha\|Long, Ling-Yun\|Chen, Tian-Wei\|Zhang, Er-Bin\|Feng, Yuan-Yuan\|Bao, Wen-Dai\|Deng, Yue-Zhen\|Qiu, Lin\|Zhang, Xue-Li\|Koeffler, H Phillip\|Cheng, Shu-qun\|Li, Jing-Jing\|Xie, Dong
PMID:	26257239

191.
Journal:	Mol Med Rep. 2015 Nov;12(5):7735-41.
Title:	Taspine derivative TAS9 regulates cell growth and metastasis of human hepatocellular carcinoma.
Author:	Liu, Rui\|Wang, Wenjie\|Dai, Bingling\|Liu, Yanping\|Zhang, Yanmin
PMID:	26459497

192.
Journal:	Dig Dis. 2015 Oct;33(6):771-9.
Title:	Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Author:	Nishida, Naoshi\|Kitano, Masayuki\|Sakurai, Toshiharu\|Kudo, Masatoshi
PMID:	26488287

193.
Journal:	J Cancer. 2015 Sep 16;6(12):1195-205.
Title:	Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma.
Author:	Ewald, Florian\|Norz, Dominik\|Grottke, Astrid\|Bach, Johanna\|Herzberger, Christiane\|Hofmann, Bianca T\|Nashan, Bjorn\|Jucker, Manfred
PMID:	26535060

194.
Journal:	World J Gastroenterol. 2015 Nov 14;21(42):12059-70.
Title:	Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
Author:	Gao, Jian-Jun\|Shi, Zhen-Yan\|Xia, Ju-Feng\|Inagaki, Yoshinori\|Tang, Wei
PMID:	26576091

195.
Journal:	Food Nutr Res. 2015 Dec 22;59:29884.
Title:	Raf/ERK/Nrf2 signaling pathway and MMP-7 expression involvement in the trigonelline-mediated inhibition of hepatocarcinoma cell migration.
Author:	Liao, Jung Chun\|Lee, Kun Tsung\|You, Bang Jau\|Lee, Chia Lin\|Chang, Wen Te\|Wu, Yang Chang\|Lee, Hong-Zin
PMID:	26699938

196.
Journal:	Rev Urol. 2015;17(4):250-1.
Title:	Sorafenib-induced Scrotal Eczema.
Author:	Caliskan, Selahattin
PMID:	26839524

197.
Journal:	Mol Carcinog. 2016 May;55(5):440-57.
Title:	Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells.
Author:	Liu, Wei\|Ning, Rui\|Chen, Rui-Ni\|Huang, Xue-Feng\|Dai, Qin-Sheng\|Hu, Jin-Hua\|Wang, Yu-Wen\|Wu, Li-Li\|Xiong, Jing\|Hu, Gang\|Guo, Qing-Long\|Yang, Jian\|Wang, Hao
PMID:	25683703

198.
Journal:	Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):9-14.
Title:	TERT promoter mutations in primary liver tumors.
Author:	Nault, Jean-Charles\|Zucman-Rossi, Jessica
PMID:	26336998

199.
Journal:	Oncogene. 2016 May 19;35(20):2547-61.
Title:	Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Author:	Mandal, R\|Becker, S\|Strebhardt, K
PMID:	26364606

200.
Journal:	Cancer Lett. 2016 Feb 1;371(1):107-16.
Title:	Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.
Author:	Zhang, Qi\|Wei, Liang\|Yang, Hongchuan\|Yang, Wanqi\|Yang, Qingyu\|Zhang, Zhuofan\|Wu, Kailang\|Wu, Jianguo
PMID:	26620707

201.
Journal:	Cancer Lett. 2016 Feb 28;371(2):171-81.
Title:	MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Author:	Xu, Yanmin\|Huang, Ji\|Ma, Leina\|Shan, Juanjuan\|Shen, Junjie\|Yang, Zhi\|Liu, Limei\|Luo, Yongli\|Yao, Chao\|Qian, Cheng
PMID:	26655273

202.
Journal:	Cell Cycle. 2016;15(4):573-83.
Title:	A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells.
Author:	Augello, Giuseppa\|Puleio, Roberto\|Emma, Maria Rita\|Cusimano, Antonella\|Loria, Guido R\|McCubrey, James A\|Montalto, Giuseppe\|Cervello, Melchiorre
PMID:	26794644

203.
Journal:	Oncotarget. 2016 May 3;7(18):25087-102.
Title:	Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections.
Author:	Tornesello, Maria Lina\|Buonaguro, Luigi\|Izzo, Francesco\|Buonaguro, Franco M
PMID:	26943571

204.
Journal:	Oncotarget. 2016 Jul 5;7(27):42598-42607.
Title:	Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Author:	Lei, Jianyong\|Zhong, Jinjing\|Hao, Jingcheng\|Liu, Zhengni\|Zhang, Peng\|Wu, Lixue\|Yan, Lunan\|Zhu, Jinqiang\|Zeng, Yong\|Li, Bo\|Wen, Tianfu\|Wang, Wentao
PMID:	26981887

205.
Journal:	Oncotarget. 2016 Jul 19;7(29):46750-46767.
Title:	The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.
Author:	Chong, Dawn Q\|Zhu, Andrew X
PMID:	27102149

206.
Journal:	Oncotarget. 2016 Jun 14;7(24):36767-36782.
Title:	Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Author:	Cui, Shu-Xiang\|Shi, Wen-Na\|Song, Zhi-Yu\|Wang, Shu-Qing\|Yu, Xin-Feng\|Gao, Zu-Hua\|Qu, Xian-Jun
PMID:	27167344

207.
Journal:	Gastroenterology. 2016 Aug;151(2):324-337.e12.
Title:	Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma.
Author:	Kodama, Takahiro\|Bard-Chapeau, Emilie A\|Newberg, Justin Y\|Kodama, Michiko\|Rangel, Roberto\|Yoshihara, Kosuke\|Ward, Jerrold M\|Jenkins, Nancy A\|Copeland, Neal G
PMID:	27178121

208.
Journal:	Crit Rev Oncol Hematol. 2016 Sep;105:65-72.
Title:	Hepatocellular carcinoma: Exploring the impact of ethnicity on molecular biology.
Author:	Lamarca, Angela\|Mendiola, Marta\|Barriuso, Jorge
PMID:	27372199

209.
Journal:	Mol Cancer Ther. 2016 Nov;15(11):2553-2562.
Title:	Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Author:	Singh, Alok R\|Joshi, Shweta\|Burgoyne, Adam M\|Sicklick, Jason K\|Ikeda, Sadakatsu\|Kono, Yuko\|Garlich, Joseph R\|Morales, Guillermo A\|Durden, Donald L
PMID:	27496136

210.
Journal:	World J Gastrointest Pathophysiol. 2016 Aug 15;7(3):242-55.
Title:	Immunobiology of hepatocarcinogenesis: Ways to go or almost there?
Author:	Patel, Pavan\|Schutzer, Steven E\|Pyrsopoulos, Nikolaos
PMID:	27574562

211.
Journal:	BMC Cancer. 2016 Sep 21;16(1):742.
Title:	Bicyclol induces cell cycle arrest and autophagy in HepG2 human hepatocellular carcinoma cells through the PI3K/AKT and Ras/Raf/MEK/ERK pathways.
Author:	Wang, Yu\|Nie, Hao\|Zhao, Xin\|Qin, Yong\|Gong, Xingguo
PMID:	27654866

212.
Journal:	Food Funct. 2016 Oct 12;7(10):4170-4174.
Title:	delta and gamma tocotrienols suppress human hepatocellular carcinoma cell proliferation via regulation of Ras-Raf-MEK-ERK pathway-associated upstream signaling.
Author:	Burdeos, Gregor Carpentero\|Ito, Junya\|Eitsuka, Takahiro\|Nakagawa, Kiyotaka\|Kimura, Fumiko\|Miyazawa, Teruo
PMID:	27713963

213.
Journal:	Oncol Lett. 2016 Nov;12(5):3045-3050.
Title:	The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC.
Author:	Li, Lei\|Zhao, Guo-Dong\|Shi, Zhe\|Qi, Li-Li\|Zhou, Li-Yuan\|Fu, Ze-Xian
PMID:	27899961

214.
Journal:	Nat Commun. 2016 Dec 21;7:13781.
Title:	A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis.
Author:	Jeric, Ines\|Maurer, Gabriele\|Cavallo, Anna Lina\|Raguz, Josipa\|Desideri, Enrico\|Tarkowski, Bartosz\|Parrini, Matthias\|Fischer, Irmgard\|Zatloukal, Kurt\|Baccarini, Manuela
PMID:	28000790

215.
Journal:	Crit Rev Oncog. 2016;21(5-6):413-432.
Title:	Antitumoral Activity of Sorafenib in Hepatocellular Carcinoma: Effects on Cell Survival and Death Pathways, Cell Metabolism Reprogramming, and Nitrosative and Oxidative Stress.
Author:	Molina-Ruiz, Francisco J\|Gonzalez, Raul\|Rodriguez-Hernandez, Maria A\|Navarro-Villaran, Elena\|Padillo, Francisco J\|Muntane, Jordi
PMID:	29431086

216.
Journal:	Hepatol Res. 2017 Mar;47(4):251-265.
Title:	Promising new strategies for hepatocellular carcinoma.
Author:	Nakamoto, Yasunari
PMID:	27558453

217.
Journal:	Curr Pharm Des. 2017;23(1):170-175.
Title:	Targeting Signalling Pathways in Hepatocellular Carcinoma.
Author:	Blagotinsek, Kaja\|Rozman, Damjana
PMID:	27719638

218.
Journal:	Biomed Pharmacother. 2017 Feb;86:27-31.
Title:	Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
Author:	Lin, Zu-Yau\|Chuang, Wan-Long
PMID:	27936391

219.
Journal:	Cancer Lett. 2017 Apr 28;392:1-8.
Title:	Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Author:	Saidak, Zuzana\|Giacobbi, Anne-Sophie\|Louandre, Christophe\|Sauzay, Chloe\|Mammeri, Youcef\|Galmiche, Antoine
PMID:	28161506

220.
Journal:	Dig Liver Dis. 2017 Jun;49(6):697-704.
Title:	Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Author:	Turcios, Lilia\|Vilchez, Valery\|Acosta, Luis F\|Poyil, Pratheeshkumar\|Butterfield, David Allan\|Mitov, Mihail\|Marti, Francesc\|Gedaly, Roberto
PMID:	28179093

221.
Journal:	Oncol Rep. 2017 Apr;37(4):2270-2276.
Title:	Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
Author:	Chiba, Naokazu\|Ozawa, Yosuke\|Hikita, Kosuke\|Okihara, Masaaki\|Sano, Toru\|Tomita, Koichi\|Takano, Kiminori\|Kawachi, Shigeyuki
PMID:	28260092

222.
Journal:	Oncol Res. 2017 Nov 2;25(9):1543-1553.
Title:	Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Author:	Tan, Wenliang\|Zhu, Sicong\|Cao, Jun\|Zhang, Lei\|Li, Wenda\|Liu, Kairui\|Zhong, Jinyi\|Shang, Changzhen\|Chen, Yajin
PMID:	28276313

223.
Journal:	Sci Rep. 2017 Mar 9;7:44123.
Title:	Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Author:	Chen, Yunching\|Liu, Ya-Chi\|Sung, Yun-Chieh\|Ramjiawan, Rakesh R\|Lin, Ts-Ting\|Chang, Chih-Chun\|Jeng, Kuo-Shyang\|Chang, Chiung-Fang\|Liu, Chun-Hung\|Gao, Dong-Yu\|Hsu, Fu-Fei\|Duyverman, Annique M\|Kitahara, Shuji\|Huang, Peigen\|Dima, Simona\|Popescu, Irinel\|Flaher
PMID:	28276530

224.
Journal:	Gastroenterology. 2017 Jun;152(8):2022-2036.
Title:	Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Author:	Chen, Bin\|Wei, Wei\|Ma, Li\|Yang, Bin\|Gill, Ryan M\|Chua, Mei-Sze\|Butte, Atul J\|So, Samuel
PMID:	28284560

225.
Journal:	Oncotarget. 2017 Apr 18;8(16):27263-27276.
Title:	SHP2 is induced by the HBx-NF-kappaB pathway and contributes to fibrosis during human early hepatocellular carcinoma development.
Author:	Kang, Hyo Jeong\|Chung, Dal-Hee\|Sung, Chang Ohk\|Yoo, Su Hyun\|Yu, Eunsil\|Kim, Nayoung\|Lee, Sy-Hye\|Song, Ji-Young\|Kim, Chong Jai\|Choi, Jene
PMID:	28460481

226.
Journal:	Am J Cancer Res. 2017 May 1;7(5):1068-1083. eCollection 2017.
Title:	Flot2 promotes tumor growth and metastasis through modulating cell cycle and inducing epithelial-mesenchymal transition of hepatocellular carcinoma.
Author:	Wang, Cheng-Hao\|Zhu, Xiao-Dong\|Ma, De-Ning\|Sun, Hui-Chuan\|Gao, Dong-Mei\|Zhang, Ning\|Qin, Cheng-Dong\|Zhang, Yuan-Yuan\|Ye, Bo-Gen\|Cai, Hao\|Shi, Wen-Kai\|Cao, Man-Qin\|Tang, Zhao-You
PMID:	28560058

227.
Journal:	Int J Oncol. 2017 Jul;51(1):128-144.
Title:	Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
Author:	Abeni, Edoardo\|Salvi, Alessandro\|Marchina, Eleonora\|Traversa, Michele\|Arici, Bruna\|De Petro, Giuseppina
PMID:	28560380

228.
Journal:	Cell Death Differ. 2017 Sep;24(9):1577-1587.
Title:	Hepatitis B virus X protein promotes CREB-mediated activation of miR-3188 and Notch signaling in hepatocellular carcinoma.
Author:	Zhou, Shao-Jun\|Deng, Yue-Ling\|Liang, Hui-Fang\|Jaoude, Jonathan C\|Liu, Fu-Yao
PMID:	28574502

229.
Journal:	Cancer Lett. 2017 Aug 28;402:71-80.
Title:	Zic2 promotes tumor growth and metastasis via PAK4 in hepatocellular carcinoma.
Author:	Lu, Shi-Xun\|Zhang, Chris Zhiyi\|Luo, Rong-Zhen\|Wang, Chun-Hua\|Liu, Li-Li\|Fu, Jia\|Zhang, Lanjing\|Wang, Huamin\|Xie, Dan\|Yun, Jing-Ping
PMID:	28577975

230.
Journal:	Arch Virol. 2017 Oct;162(10):2937-2947.
Title:	Modulation of Wnt signaling pathway by hepatitis B virus.
Author:	Daud, Muhammad\|Rana, Muhammad Adeel\|Husnain, Tayyab\|Ijaz, Bushra
PMID:	28685286

231.
Journal:	Oncol Lett. 2017 Jul;14(1):517-524.
Title:	Sorafenib induced alteration of protein glycosylation in hepatocellular carcinoma cells.
Author:	Liu, Tianhua\|Liu, Riqiang\|Zhang, Shu\|Guo, Kun\|Zhang, Qinle\|Li, Wei\|Liu, Yinkun
PMID:	28693200

232.
Journal:	Biomed Pharmacother. 2017 Sep;93:1025-1032.
Title:	MicroRNA-30a suppresses tumor progression by blocking Ras/Raf/MEK/ERK signaling pathway in hepatocellular carcinoma.
Author:	Zhou, Kun\|Luo, Xiaoyu\|Wang, Yu\|Cao, Dachun\|Sun, Gang
PMID:	28732393

233.
Journal:	Mol Cancer. 2017 Sep 11;16(1):152.
Title:	Cell-specific mechanisms of TMEM16A Ca(2+)-activated chloride channel in cancer.
Author:	Wang, Hui\|Zou, Liang\|Ma, Ke\|Yu, Jiankun\|Wu, Huizhe\|Wei, Minjie\|Xiao, Qinghuan
PMID:	28893247

234.
Journal:	Cancer Med. 2017 Dec;6(12):2787-2795.
Title:	Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Author:	Liang, Yuelong\|Chen, Jiang\|Yu, Qingsong\|Ji, Tong\|Zhang, Bin\|Xu, Junjie\|Dai, Yi\|Xie, Yangyang\|Lin, Hui\|Liang, Xiao\|Cai, Xiujun
PMID:	29030911

235.
Journal:	Oncotarget. 2017 Nov 6;8(63):107096-107108.
Title:	Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma.
Author:	Kissel, Maria\|Berndt, Sandra\|Fiebig, Lukas\|Kling, Simon\|Ji, Qunsheng\|Gu, Qingyang\|Lang, Tina\|Hafner, Frank-Thorsten\|Teufel, Michael\|Zopf, Dieter
PMID:	29291014

236.
Journal:	Biomed Pharmacother. 2018 Jan;97:1282-1288.
Title:	Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Author:	Lu, Mingxia\|Fei, Zhenghua\|Zhang, Ganlu
PMID:	29156516

237.
Journal:	Oncol Rep. 2018 Feb;39(2):843-850.
Title:	Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Author:	Yokoi, Kenta\|Kobayashi, Akira\|Motoyama, Hiroaki\|Kitazawa, Masato\|Shimizu, Akira\|Notake, Tsuyoshi\|Yokoyama, Takahide\|Matsumura, Tomio\|Takeoka, Michiko\|Miyagawa, Shin-Ichi
PMID:	29251327

238.
Journal:	Gut. 2018 Jul;67(7):1328-1341.
Title:	Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Author:	Dietrich, Peter\|Koch, Andreas\|Fritz, Valerie\|Hartmann, Arndt\|Bosserhoff, Anja Katrin\|Hellerbrand, Claus
PMID:	29275358

239.
Journal:	Cancer Res. 2018 May 1;78(9):2219-2232.
Title:	Demethylation-Induced Overexpression of Shc3 Drives c-Raf-Independent Activation of MEK/ERK in HCC.
Author:	Liu, Yun\|Zhang, Xinran\|Yang, Baicai\|Zhuang, Hao\|Guo, Hua\|Wei, Wen\|Li, Yuan\|Chen, Ruibing\|Li, Yongmei\|Zhang, Ning
PMID:	29330146

240.
Journal:	BMB Rep. 2018 Mar;51(3):119-125.
Title:	Clinical implications of the Hippo-YAP pathway in multiple cancer contexts.
Author:	Kim, Han-Byul\|Myung, Seung-Jae
PMID:	29366445

241.
Journal:	World J Hepatol. 2018 Jan 27;10(1):155-165.
Title:	Epigenetic basis of hepatocellular carcinoma: A network-based integrative meta-analysis.
Author:	Bhat, Venkat\|Srinathan, Sujitha\|Pasini, Elisa\|Angeli, Marc\|Chen, Emily\|Baciu, Cristina\|Bhat, Mamatha
PMID:	29399289

242.
Journal:	Oncoimmunology. 2017 Dec 13;7(3):e1408745.
Title:	Monocytes/Macrophages promote vascular CXCR4 expression via the ERK pathway in hepatocellular carcinoma.
Author:	Meng, Ya-Ming\|Liang, Jing\|Wu, Chong\|Xu, Jing\|Zeng, Dan-Ni\|Yu, Xing-Juan\|Ning, Huiheng\|Xu, Li\|Zheng, Limin
PMID:	29399411

243.
Journal:	Sci Rep. 2018 Feb 5;8(1):2375.
Title:	miR-429 suppresses tumor migration and invasion by targeting CRKL in hepatocellular carcinoma via inhibiting Raf/MEK/ERK pathway and epithelial-mesenchymal transition.
Author:	Guo, Chunmei\|Zhao, Dongting\|Zhang, Qiuling\|Liu, Shuqing\|Sun, Ming-Zhong
PMID:	29403024

244.
Journal:	Oncotarget. 2017 Dec 11;9(3):3605-3618.
Title:	Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic "dual-hit" option.
Author:	Dietrich, Peter\|Freese, Kim\|Mahli, Abdo\|Thasler, Wolfgang Erwin\|Hellerbrand, Claus\|Bosserhoff, Anja Katrin
PMID:	29423069

245.
Journal:	Cell Death Dis. 2018 Feb 15;9(3):269.
Title:	EGFR-PI3K-PDK1 pathway regulates YAP signaling in hepatocellular carcinoma: the mechanism and its implications in targeted therapy.
Author:	Xia, Hongwei\|Dai, Xinyu\|Yu, Huangfei\|Zhou, Sheng\|Fan, Zhenghai\|Wei, Guoqing\|Tang, Qiulin\|Gong, Qiyong\|Bi, Feng
PMID:	29449645

246.
Journal:	Theranostics. 2018 Jan 1;8(4):894-905.
Title:	Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development.
Author:	Sung, Yun-Chieh\|Liu, Ya-Chi\|Chao, Po-Han\|Chang, Chih-Chun\|Jin, Pei-Ru\|Lin, Ts-Ting\|Lin, Ja-An\|Cheng, Hui-Teng\|Wang, Jane\|Lai, Charles P\|Chen, Ling-Hsuan\|Wu, Anthony Y\|Ho, Ting-Lun\|Chiang, Tsaiyu\|Gao, Dong-Yu\|Duda, Dan G\|Chen, Yunching
PMID:	29463989

247.
Journal:	Mol Med Rep. 2018 Apr;17(4):6185-6193.
Title:	Anticancer effects of a novel PanRAF inhibitor in a hepatocellular carcinoma cell line.
Author:	Wang, Wei\|Xu, Bo\|Li, Qixiang\|Jiang, Dechun\|Yan, Suying
PMID:	29484394

248.
Journal:	Transl Oncol. 2018 Apr;11(2):511-517.
Title:	Inhibition of pMAPK14 Overcomes Resistance to Sorafenib in Hepatoma Cells with Hepatitis B Virus.
Author:	Witt-Kehati, Dvora\|Fridkin, Alexandra\|Alaluf, Maya Bitton\|Zemel, Romy\|Shlomai, Amir
PMID:	29524828

249.
Journal:	Liver Int. 2018 Apr 14.
Title:	Sp1-regulated transcription of RasGRP1 promotes hepatocellular carcinoma (HCC) proliferation.
Author:	Zhang, Xinran\|Zhuang, Hao\|Han, Feng\|Shao, Xiaowen\|Liu, Yun\|Ma, Xuda\|Wang, Zun\|Qiang, Zhaoyan\|Li, Yongmei
PMID:	29655291

250.
Journal:	Cell Death Dis. 2018 May 1;9(5):486.
Title:	The Rho GTPase Rnd1 inhibits epithelial-mesenchymal transition in hepatocellular carcinoma and is a favorable anti-metastasis target.
Author:	Qin, Cheng-Dong\|Ma, De-Ning\|Zhang, Shi-Zhe\|Zhang, Ning\|Ren, Zheng-Gang\|Zhu, Xiao-Dong\|Jia, Qing-An\|Chai, Zong-Tao\|Wang, Cheng-Hao\|Sun, Hui-Chuan\|Tang, Zhao-You
PMID:	29706627

251.
Journal:	Anticancer Agents Med Chem. 2018 May 7. pii: ACAMC-EPUB-90231.
Title:	HCC Specific Protein Network Involving Interactions of EGFR with A-Raf and Transthyretin: Experimental Analysis and Computational Biology Correlates.
Author:	Ranjpour, Maryam\|Katare, Deepshikha Pande\|Wajid, Saima\|Jain, Swatantra Kumar
PMID:	29732980

252.
Journal:	Int J Cancer. 2018 May 11.
Title:	HBV suppresses ZHX2 expression to promote proliferation of HCC through miR-155 activation.
Author:	Song, Xiaojia\|Tan, Siyu\|Wu, Zhuanchang\|Xu, Leiqi\|Wang, Zehua\|Xu, Yong\|Wang, Tixiao\|Gao, Chengjiang\|Gong, Yaoqin\|Liang, Xiaohong\|Gao, Lifen\|Spear, Brett T\|Ma, Chunhong
PMID:	29752719

253.
Journal:	J Gastrointest Cancer. 2018 Sep;49(3):227-236.
Title:	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies.
Author:	da Motta Girardi, Daniel\|Correa, Tatiana Strava\|Crosara Teixeira, Marcela\|Dos Santos Fernandes, Gustavo
PMID:	29806062

254.
Journal:	Bioorg Chem. 2018 Sep;79:355-362.
Title:	Pyran-2-one derivatives from Croton crassifolius as potent apoptosis inducers in HepG2 cells via p53-mediated Ras/Raf/ERK pathway.
Author:	Tian, Jin-Long\|Yao, Guo-Dong\|Zhang, Ying-Ying\|Lin, Bin\|Zhang, Yan\|Li, Ling-Zhi\|Huang, Xiao-Xiao\|Song, Shao-Jiang
PMID:	29852310

255.
Journal:	J Cancer Res Clin Oncol. 2018 Aug;144(8):1487-1501.
Title:	Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Author:	Kim, Jin Sun\|Choi, Gwang Hyeon\|Jung, Yusun\|Kim, Kang Mo\|Jang, Se-Jin\|Yu, Eun Sil\|Lee, Han Chu
PMID:	29858683

256.
Journal:	Hepatol Commun. 2018 Apr 17;2(6):732-746.
Title:	Inhibition of insulin-like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival.
Author:	Wang, Fang\|Bank, Thomas\|Malnassy, Gregory\|Arteaga, Maribel\|Shang, Na\|Dalheim, Annika\|Ding, Xianzhong\|Cotler, Scott J\|Denning, Mitchell F\|Nishimura, Michael I\|Breslin, Peter\|Qiu, Wei
PMID:	29881824

257.
Journal:	Recent Results Cancer Res. 2018;211:45-56.
Title:	Regorafenib.
Author:	Ettrich, Thomas J\|Seufferlein, Thomas
PMID:	30069758

258.
Journal:	Hepatobiliary Pancreat Dis Int. 2018 Aug;17(4):336-344.
Title:	MicroRNA-449a suppresses hepatocellular carcinoma cell growth via G1 phase arrest and the HGF/MET c-Met pathway.
Author:	Cheng, Jun\|Wu, Li-Ming\|Deng, Xue-Song\|Wu, Jian\|Lv, Zhen\|Zhao, Hang-Fen\|Yang, Zhang\|Ni, Yong
PMID:	30108016

259.
Journal:	Drug Metab Dispos. 2018 Aug 16. pii: dmd.118.083014.
Title:	Mouse hepatomas with Ha-ras and B-raf mutations differ in mitogen-activated protein kinase signaling and response to constitutive androstane receptor activation.
Author:	Braeuning, Albert\|Kollotzek, Ferdinand\|Zeller, Eva\|Knorpp, Thomas\|Templin, Markus F\|Schwarz, Michael
PMID:	30115646

260.
Journal:	Biochem Biophys Res Commun. 2018 Sep 18;503(4):3023-3030.
Title:	The role of Zhx2 transcription factor in bipolar cell differentiation during mouse retinal development.
Author:	Kawamura, Yuichi\|Yamanaka, Kyohei\|Poh, Boonmin\|Kuribayashi, Hiroshi\|Koso, Hideto\|Watanabe, Sumiko
PMID:	30146259

261.
Journal:	Life Sci. 2018 Oct 4. pii: S0024-3205(18)30619-2.
Title:	Inhibition of SRC/FAK cue: A novel pathway for the synergistic effect of rosuvastatin on the anti-cancer effect of dasatinib in hepatocellular carcinoma.
Author:	El Sayed, Ibrahim\|Helmy, Maged W\|El-Abhar, Hanan S
PMID:	30292831

262.
Journal:	Zhonghua Gan Zang Bing Za Zhi. 2018 Aug 20;26(8):601-606.
Title:	[Mechanism of angiotensin II (Ang II) on the proliferation of human hepatoma cell line HepG2 cells].
Author:	Qi, R\|Lei, C G\|Bai, Y X\|Xing, X
PMID:	30317792

263.
Journal:	Anticancer Agents Med Chem. 2018 Oct 15. pii: ACAMC-EPUB-93678.
Title:	Elevated expression of A-Raf and FA2H in hepatocellular carcinoma is associated with lipid metabolism dysregulation and cancer progression.
Author:	Ranjpour, Maryam\|Wajid, Saima\|Jain, Swatantra Kumar
PMID:	30324893

264.
Journal:	Cell Rep. 2018 Oct 16;25(3):690-701.e8.
Title:	PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.
Author:	Chan, Lok Hei\|Zhou, Lei\|Ng, Kai Yu\|Wong, Tin Lok\|Lee, Terence K\|Sharma, Rakesh\|Loong, Jane H\|Ching, Yick Pang\|Yuan, Yun-Fei\|Xie, Dan\|Lo, Chung Mau\|Man, Kwan\|Artegiani, Benedetta\|Clevers, Hans\|Yan, Helen H\|Leung, Suet Yi\|Richard, Stephane\|Guan, Xin-Yuan\|Hu
PMID:	30332648

265.
Journal:	Clin Res Hepatol Gastroenterol. 2018 Oct 27. pii: S2210-7401(18)30216-X.
Title:	Interplay of Wnt beta-catenin pathway and miRNAs in HBV pathogenesis leading to HCC.
Author:	Rana, Muhammad Adeel\|Ijaz, Bushra\|Daud, Muhammad\|Tariq, Sommyya\|Nadeem, Tariq\|Husnain, Tayyab
PMID:	30377095